Böker K H, Ringe B, Krüger M, Pichlmayr R, Manns M P
Department of Gastroenterology and Hepatology, Medizinische, Hochschule Hannover, Germany.
Transplantation. 1994 Jun 27;57(12):1706-8.
New concepts for the treatment of hepatitis B in immunocompromised patients are urgently needed. We describe our first experience with the new antiviral agent famciclovir in combination with a short course of prostaglandin E in a patient with severe hepatitis B after liver transplantation. Initial treatment with prostaglandin E reduced the inflammatory activity, as measured by transaminase activities, but did not affect viral replication. Consecutive long-term treatment with famciclovir further normalized liver function and profoundly suppressed viral replication. HBeAg and HBV-DNA -PCR all became negative and only HBsAg persisted. Histology documented marked reduction of cellular infiltration. The patient completely recovered and is back to regular work as a teacher.
免疫功能低下患者的乙型肝炎治疗急需新的理念。我们描述了我们对一名肝移植后患有严重乙型肝炎的患者使用新型抗病毒药物泛昔洛韦联合短期前列腺素E的首次经验。前列腺素E的初始治疗降低了炎症活性，通过转氨酶活性来衡量，但并未影响病毒复制。连续长期使用泛昔洛韦进一步使肝功能恢复正常，并显著抑制了病毒复制。HBeAg和HBV-DNA -PCR均转为阴性，仅HBsAg持续存在。组织学检查记录显示细胞浸润明显减少。该患者已完全康复，现作为一名教师恢复了正常工作。
